Roche Pharmaceuticals (Israel) Ltd

Interleukin-6 Receptor Inhibitor. Tocilizumab 20 mg/ml.
VIALS: 1, 4 x 80 mg/4 ml; 200mg/10 ml;
400 mg/20 ml.
RA : 8mg/kg bdy wt. I.V. 1 x every 4
weeks.
Pts. bdy wt. > 100 kg, dose exceed. 800
mg/infus. not recommend. See lit. SJIA:
<30 kg bdywt: 12 mg/kg bdywt, every
2 wks; ≥30 kg bdywt: 8 mg/kg bdywt,
every 2 wks.
Reduce signs/sympts. in adult pts with
mod-severe active rheum. arthrit. when
inad. response to one/more DMARDS or
TNF antags., or in pts unable to use
DMARDs. Can be used alone/in comb. with
methotrexate/other DMARDs. Reduce rate
progress. joint damage as measured by
X-ray, improve physic. funct. when in
combinat. methotrexate. Tmt. active
system. juv. idiopath. arthrit. in pts. > 2 yrs.
C/I: Hypersens., active severe infects.

Interleukin-6 Receptor Inhibitor. Tocilizumab 162 mg / 0.9 ml.
PRE- FILLED SYRINGE.: 4 x 162 mg/0.9 ml
Inj. S.C. 162 mg once a week.
In comb. with MTX, for the tmt. of moder.-
severe active RA in adult pt. who have
either responded inadequate. to, or who
were intoler. to, prev. therapy with one or
more DMARDs or TNF antagonists. In
these pts., Tocilizumab can be given as
monother. in case of intolerance to MTX or
where continued tmt. with MTX is
inappropriate.
C/I: Hypersens., active severe infects.

Protein Kinase Inhibitor. Alectinib 150 mg.
HARD CAPS.:240.
600 mg (4×150 mg caps.) ×2/d with food , max. dly. dose of 1200 mg). See lit.
Tmt. of pts. with ALK posit., local. advanc. or metast. non-small cell lung cancer (NSCLC) who progres. on or are intolerant to crizotinib. Alectinib as monother. - for the 1^st -line tmt. of adult pts. with anaplastic lymphoma kinase (ALK)-posit. advanc. non-small cell lung cancer. (NSCLC).
C/I: Hypersens.

Monoclonal Antibody, VEGF Inhibitor. Bevacizumab 25 mg/ml.
VIALS: 1 x 100 mg/4 ml; 1 x 400
mg/16ml.
Dosage adjust. individ. for each pt.
accord to the med. cond. accord. to
prescr. info.
Tmt. metastat. Carcinoma of the colon or
rectum, to be used in combinat. With
fluoropyrimidine-based chemother.
Firstline tmt. metastat. Breast cancer, in
comb. with Paclitaxel. tmt.
unresect.,advanced, metastat./recurrent
NSCLC other than predom. squamous cell
histology, in add. to platinum-based
chemother. tmt. advanc./metastat. Renal
cell cancer, in comb. with interferon alfa-
2a. Firstline tmt. advanc./metastat. Renal
cell cancer, in comb. with interferon alfa-
2a. As single agent tmt. glioblastom. In
pts. with progress. dis. foll. prior ther.
Front-line tmt. in comb. with paclitaxel.
and carboplatin advanc. (FIGO III B, III
C,IV) epithelial ovar., fallop. tube, or
primary peritoneal canc. in pts at high risk
for recurrence (resid. dis. aft.debulk.). in
comb. with carboplatin and gemcitabine
tmt of adult pts. with first recur.of
platinum-sensit. epithelial ovar., fallopian
tube or prim. peritoneal cancer who have
not received prior therapy with
Bevacizumab or other VEGF inhibit. or
VEGF receptor–targeted agents.
C/I: Hypersens. active substance/
excips./ chinese hamster ovary/ other recombinant human or humanized
antibodies., pregn.

Immunosuppressant. Mycophenolate Mofetil 250 mg, 500 mg.
CAPS: 100 x 250 mg.
F.C. TABS: 50 x 500 mg. Dosage must me
adjust. individ. accord. to indication and pt medic. condit. See lit.
Concom. use with cyclosporine and
corticosteroids for proph. of organ reject.
in pts. receiv. allogen. ren., card. and
hepat. transplants.
C/I: Hypersensitivity to mycophenolate
mofetil /mycophenolic acid. Lact.
WOCBP who are not using highly
effective contracept. Mycophenolate
mofetil tmt. should not be init. in
WOCBP without providing a preg. test
result to rule out unintended use in
preg. Mycophenolate mofetil should not
be used during preg. unless there is no
suitable alternative tmt. to prevent
transplant rejection.

Protein Kinase Inhibitor. Cobimetinib Hemifumarate 20 mg.
F.C. TABS.:63.
60 mg (3 tabs. of 20 mg) once dly., taken on a 28 day cycle. 21 consecutive d.  (1^st  -21^st day -tmt. period); follow.by a 7-day break (22^nd -28^th –tmt. break).  Each subseq. tmt. cycle should start after the 7-day tmt. break has elapsed. See lit.
Indicat.  for use in comb.  with vemurafenib for the tmt. of adult pts. with unresectab. or metastat. melanoma with a BRAF V600 mutation.
C/I: Hypersens.